NSD3 and neoplasm: Interestingly, among patients with NC treated with molibresib, PRs (confirmed and unconfirmed) were mostly observed in tumours with BRD3-NUT fusions.32 Similarly, minor but sustained regression has also been reported in a patient with NC harbouring BRD3-NUT fusion treated with BMS-986158.34 Although all known NUT fusions depend on BRD3/BRD4 for their oncogenic function in NC, regardless of whether the NUT fusion partner is a BET protein, it is not known whether chromatin binding of BRD3-NUT and NSD3-NUT is more easily disrupted by competitive BET inhibition than that of BRD4-NUT.